United States securities and exchange commission logo

                             July 7, 2021

       Thomas Zindrick, J.D.
       President and Chief Executive Officer
       Genelux Corporation
       3030 Bunker Hill Street, Suite 300
       San Diego, CA 92109

                                                        Re: Genelux Corporation
                                                            Amendment No. 1 to
Draft Registration Statement on Form S-1
                                                            Submitted June 24,
                                                            CIK No. 0001231457

       Dear Mr. Zindrick:

            We have reviewed your amended draft registration statement and have
the following

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comment applies to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your

             After reviewing the information you provide in response to this
comment and your
       amended draft registration statement or filed registration statement, we
may have additional

       Amendment No. 1 to Draft Registration Statement on Form S-1 submitted
June 24, 2021

       Ovarian Cancer Program, page 114

   1.                                                   Please disclose the
material assumptions underlying the projections presented in this
 Thomas Zindrick, J.D.
FirstName   LastNameThomas Zindrick, J.D.
Genelux Corporation
July 7, 2021NameGenelux Corporation
July 7,2 2021 Page 2
FirstName LastName
        You may contact Tracie Mariner at 202-551-3744 or Vanessa Robertson at
if you have questions regarding comments on the financial statements and
matters. Please contact Jeffrey Gabor at 202-551-2544 or Laura Crotty at
202-551-7614 with
any other questions.


                                                        Division of Corporation
                                                        Office of Life Sciences
cc:      Amy Hallman Rice, Esq.